Advanced

Urinary Tract Infection Molecular Mechanisms and Clinical Translation.

Godaly, Gabriela LU ; Ambite, Ines LU ; Puthia, Manoj LU ; Nadeem, Aftab LU ; Ho, James; Nagy, Károly LU ; Huang, Yujing LU ; Rydström, Gustav LU and Svanborg, Catharina LU (2016) In Pathogens (Basel, Switzerland) 5(1).
Abstract
Rapid developments in infection biology create new and exciting options for individualized diagnostics and therapy. Such new practices are needed to improve patient survival and reduce morbidity. Molecular determinants of host resistance to infection are being characterized, making it possible to identify susceptible individuals and to predict their risk for future morbidity. Immunotherapy is emerging as a new strategy to treat infections worldwide and controlled boosting of the host immune defense represents an important therapeutic alternative to antibiotics. In proof of concept studies, we have demonstrated that this approach is feasible. The long-term goal is not just to remove the pathogens but to also develop technologies that... (More)
Rapid developments in infection biology create new and exciting options for individualized diagnostics and therapy. Such new practices are needed to improve patient survival and reduce morbidity. Molecular determinants of host resistance to infection are being characterized, making it possible to identify susceptible individuals and to predict their risk for future morbidity. Immunotherapy is emerging as a new strategy to treat infections worldwide and controlled boosting of the host immune defense represents an important therapeutic alternative to antibiotics. In proof of concept studies, we have demonstrated that this approach is feasible. The long-term goal is not just to remove the pathogens but to also develop technologies that restore resistance to infection in disease-prone patients and devise personalized therapeutic interventions. Here, we discuss some approaches to reaching these goals, in patients with urinary tract infection (UTI). We describe critical host signaling pathways that define symptoms and pathology and the genetic control of innate immune responses that balance protection against tissue damage. For some of these genes, human relevance has been documented in clinical studies, identifying them as potential targets for immune-modulatory therapies, as a complement to antibiotics. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pathogens (Basel, Switzerland)
volume
5
issue
1
publisher
MDPI AG
external identifiers
  • pmid:26927188
  • wos:000373680700017
ISSN
2076-0817
DOI
10.3390/pathogens5010024
language
English
LU publication?
yes
id
64539a18-de0a-4c3e-97db-5553d66233b0 (old id 8857091)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26927188?dopt=Abstract
date added to LUP
2016-03-15 09:51:48
date last changed
2016-09-30 05:48:03
@article{64539a18-de0a-4c3e-97db-5553d66233b0,
  abstract     = {Rapid developments in infection biology create new and exciting options for individualized diagnostics and therapy. Such new practices are needed to improve patient survival and reduce morbidity. Molecular determinants of host resistance to infection are being characterized, making it possible to identify susceptible individuals and to predict their risk for future morbidity. Immunotherapy is emerging as a new strategy to treat infections worldwide and controlled boosting of the host immune defense represents an important therapeutic alternative to antibiotics. In proof of concept studies, we have demonstrated that this approach is feasible. The long-term goal is not just to remove the pathogens but to also develop technologies that restore resistance to infection in disease-prone patients and devise personalized therapeutic interventions. Here, we discuss some approaches to reaching these goals, in patients with urinary tract infection (UTI). We describe critical host signaling pathways that define symptoms and pathology and the genetic control of innate immune responses that balance protection against tissue damage. For some of these genes, human relevance has been documented in clinical studies, identifying them as potential targets for immune-modulatory therapies, as a complement to antibiotics.},
  author       = {Godaly, Gabriela and Ambite, Ines and Puthia, Manoj and Nadeem, Aftab and Ho, James and Nagy, Károly and Huang, Yujing and Rydström, Gustav and Svanborg, Catharina},
  issn         = {2076-0817},
  language     = {eng},
  number       = {1},
  publisher    = {MDPI AG},
  series       = {Pathogens (Basel, Switzerland)},
  title        = {Urinary Tract Infection Molecular Mechanisms and Clinical Translation.},
  url          = {http://dx.doi.org/10.3390/pathogens5010024},
  volume       = {5},
  year         = {2016},
}